156 related articles for article (PubMed ID: 11303396)
1. [Biological compounds in the treatment of Crohn's disease].
Dinari G
Harefuah; 2001 Apr; 140(4):316-8. PubMed ID: 11303396
[No Abstract] [Full Text] [Related]
2. [What can be expected from biological therapies for Crohn's disease?].
Lemann M
Gastroenterol Clin Biol; 2001 Nov; 25(11):945-7. PubMed ID: 11845043
[No Abstract] [Full Text] [Related]
3. Treatment of patients with Crohn's disease and concomitant chronic hepatitis C with a chimeric monoclonal antibody to TNF.
Holtmann MH; Galle PR; Neurath MF
Am J Gastroenterol; 2003 Feb; 98(2):504-5. PubMed ID: 12591081
[No Abstract] [Full Text] [Related]
4. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. PRO: maintenance therapy is superior to episodic therapy.
Lichtenstein GR
Am J Gastroenterol; 2005 Jul; 100(7):1433-5. PubMed ID: 15984959
[No Abstract] [Full Text] [Related]
5. Prediction of response to infliximab in Crohn's disease.
Chaudhary R; Ghosh S
Dig Liver Dis; 2005 Aug; 37(8):559-63. PubMed ID: 15893967
[No Abstract] [Full Text] [Related]
6. Immunogenicity of infliximab in Crohn's disease.
Hanauer SB
N Engl J Med; 2003 May; 348(21):2155-6; author reply 2155-6. PubMed ID: 12761378
[No Abstract] [Full Text] [Related]
7. Investigational agents for Crohn's disease.
Cottone M; Orlando A; Renna S
Expert Opin Investig Drugs; 2010 Oct; 19(10):1147-59. PubMed ID: 20836616
[TBL] [Abstract][Full Text] [Related]
8. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
Hanauer SB
Gut; 2007 Sep; 56(9):1181-3. PubMed ID: 17698862
[TBL] [Abstract][Full Text] [Related]
9. [Selective TNF-alpha inhibition in Crohn disease. Emergency help in problem cases].
MMW Fortschr Med; 2001 May; 143(18):52. PubMed ID: 11387713
[No Abstract] [Full Text] [Related]
10. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease.
Suenaert P; Bulteel V; Lemmens L; Noman M; Geypens B; Van Assche G; Geboes K; Ceuppens JL; Rutgeerts P
Am J Gastroenterol; 2002 Aug; 97(8):2000-4. PubMed ID: 12190167
[TBL] [Abstract][Full Text] [Related]
11. Long-term partial remission of autoimmune thrombocytopenia in a patient treated with the anti-tumor necrosis factor-alpha antibody infliximab for refractory fistulizing Crohn's disease.
de Rossi TM; Krauss N; Voll RE; Nägel A; Weidenhiller M; Konturek PC; Hahn EG; Raithel M
Digestion; 2008; 78(4):195-200. PubMed ID: 19122456
[TBL] [Abstract][Full Text] [Related]
12. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease.
Schinzari F; Armuzzi A; De Pascalis B; Mores N; Tesauro M; Melina D; Cardillo C
Clin Pharmacol Ther; 2008 Jan; 83(1):70-6. PubMed ID: 17507924
[TBL] [Abstract][Full Text] [Related]
13. Challenges in Crohn's disease.
Rutgeerts PJ
Rev Gastroenterol Disord; 2004; 4 Suppl 3():S1-2. PubMed ID: 15580147
[No Abstract] [Full Text] [Related]
14. Crohn's disease, TNF-alpha, and the leaky gut. The chicken or the egg?
Hollander D
Am J Gastroenterol; 2002 Aug; 97(8):1867-8. PubMed ID: 12190145
[No Abstract] [Full Text] [Related]
15. [Infliximab--practical guidelines for the treatment of Crohn's disease].
Bauerfeind P; Beglinger C; Beltinger J; Braegger C; Eigenmann F; Fried M; Guyot J; Hürlimann R; Michetti P; Seibold F; Straumann A
Rev Med Suisse; 2006 Jul; 2(74):1807-15. PubMed ID: 16927560
[TBL] [Abstract][Full Text] [Related]
16. [Practice guidelines in gastroenterology. Use of anti-TNF agents in inflammatory bowel disease. European guide 2001-2003].
Rom J Gastroenterol; 2002 Mar; 11(1):68-71. PubMed ID: 12219731
[No Abstract] [Full Text] [Related]
17. Insufficient evidence to conclude whether anti-tumor necrosis factor therapy increases the risk of lymphoma in Crohn's disease.
Peyrin-Biroulet L; Colombel JF; Sandborn WJ
Clin Gastroenterol Hepatol; 2009 Oct; 7(10):1139. PubMed ID: 19465159
[No Abstract] [Full Text] [Related]
18. [Indications and results of infliximab in Crohn's disease].
Karoui S; Boubaker J; Filali A
Tunis Med; 2004 Dec; 82(12):1057-63. PubMed ID: 15822505
[TBL] [Abstract][Full Text] [Related]
19. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
Martínez-Borra J; López-Larrea C; González S; Fuentes D; Dieguez A; Deschamps EM; Pérez-Pariente JM; López-Vázquez A; de Francisco R; Rodrigo L
Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of Pyoderma gangrenosum associated with Crohn's disease.
Zaccagna A; Bertone A; Puiatti P; Picciotto F; Sprujevnik T; Santucci R; Rossini FP
Eur J Dermatol; 2003; 13(3):258-60. PubMed ID: 12804985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
